Close Menu

research and development

The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.

The spatial molecular imager will be NanoString's next play in a growing market that it says is worth more than $12 billion, including diagnostic applications.

Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.

The firm is also pursuing advances in its manufacturing and ordering processes that it says will help it scale to $500 million in annual revenues.

A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.

The group is developing an ultrasensitive nanoparticle-enhanced plasmonic biosensor to detect RAS single nucleotide variants in plasma.

In their first conference call with investors, PacBio's new CEO and CFO laid out a strategic plan for the company as it weathers the COVID-19 pandemic.

The funding is part of a BARDA contract worth up to $72 million to support the development of a test to diagnose acute infection at the point of care.

10x will develop a third genomics platform, possibly combining Cartana's more sensitive chemistry with ReadCoor's instrument.

The single-molecule sequencing firm is skipping a beta testing program for its new sequencer, which should be available by the end of the year.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.